McClarren Financial Advisors Inc. Trims Position in Eli Lilly and Company $LLY

Key Points

• McClarren Financial Advisors cut its Eli Lilly stake by 75.8% in the first quarter, selling 1,629 shares and leaving it with 520 shares worth about $478,000.
• Eli Lilly’s recent results remained very strong, with revenue up 55.5% to $19.80 billion and earnings beating estimates, while the company also raised full-year guidance to $82 billion-$85 billion.
• Wall Street sentiment stays bullish, with multiple analysts maintaining buy-style ratings and an average Moderate Buy rating; the stock opened at $1,098.78 and has a market cap of about $1.03 trillion.

McClarren Financial Advisors Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 75.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 520 shares of the company's stock after selling 1,629 shares during the quarter. McClarren Financial Advisors Inc.'s holdings in Eli Lilly and Company were worth $478,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the business. 10Elms LLP boosted its holdings in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after purchasing an additional 10 shares during the last quarter. M.E. Allison & CO. Inc. increased its stake in Eli Lilly and Company by 0.7% in the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock valued at $1,587,000 after purchasing an additional 10 shares during the last quarter. Tanager Wealth Management LLP lifted its position in Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock worth $424,000 after buying an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC lifted its position in Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock worth $710,000 after buying an additional 10 shares during the period. Finally, Wealthspan Partners LLC boosted its stake in Eli Lilly and Company by 0.5% in the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock worth $2,268,000 after buying an additional 10 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s latest quarter showed standout fundamentals, with revenue up 55.5% year over year to $19.80 billion and full-year guidance raised to $82 billion-$85 billion, reinforcing the company’s leadership in GLP-1 drugs like Mounjaro. Prediction: Eli Lilly Will Trade at $1,200 on This Date
• Positive Sentiment: Analysts and market commentators remain bullish, citing Lilly’s rapid earnings growth, heavy manufacturing investment, and ongoing leadership in obesity and diabetes treatments as reasons the stock could keep climbing. Under Dave Ricks, Lilly Is Minting Money on GLP-1 Drugs and Spending It Wisely
• Positive Sentiment: New collaborations around Lilly TuneLab, including partnerships with Charles River and Chai Discovery, expand the company’s AI-driven drug discovery ecosystem and could support longer-term pipeline productivity. Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs
• Neutral Sentiment: Several articles highlighted ongoing pipeline progress, including completion of trials for retatrutide and mevidalen, which are worth watching but did not include definitive late-stage results. Retatrutide Trial Completion Signals Next Step for Eli Lilly’s Diabetes Pipeline
• Neutral Sentiment: Some commentary framed Lilly as still undervalued relative to its growth narrative and pointed to AI-driven healthcare as another possible upside theme, but these pieces were largely opinion-based rather than new company-specific catalysts. Eli Lilly (LLY) Stock Could Be 24.7% Undervalued on Its Growth Narrative
• Negative Sentiment: LLY also saw a short-term pullback in the prior session, showing that even with strong fundamentals, investors have been taking some profits after the stock’s big run. Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: A report that Lilly has begun denying some 340B discounts could create friction with healthcare buyers and adds a potential reimbursement-related overhang. Eli Lilly begins denying 340B discounts

Analyst Ratings Changes

LLY has been the subject of several recent analyst reports. Rothschild & Co Redburn lifted their price target on Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an "overweight" rating in a research report on Friday, May 1st. BMO Capital Markets restated an "outperform" rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Guggenheim reaffirmed a "buy" rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Finally, Sanford C. Bernstein reiterated an "outperform" rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,227.74.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,098.78 on Monday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company's fifty day moving average price is $1,016.10 and its two-hundred day moving average price is $1,017.13. The firm has a market capitalization of $1.03 trillion, a P/E ratio of 39.03, a P/E/G ratio of 1.20 and a beta of 0.53. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,182.73.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period last year, the firm earned $3.34 earnings per share. The company's revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, May 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.